Eli Lilly stock today: drivers, numbers, and what to watch for next.
Key takeaways (Nov 6, 2025)
- LLY shares were trading higher around mid‑day after fresh catalysts, including a White House pricing-and-access deal for GLP‑1 weight‑loss medicines and new mid‑stage data showing up to 20.1% weight loss from Lilly’s next‑gen obesity candidate, eloralintide. 1
- Policy tailwind: The administration announced a plan to expand coverage and lower out‑of‑pocket costs for Zepbound/Wegovy, with Medicare coverage and discounted pricing through a new TrumpRx platform. Details vary by channel (e.g., starter doses of pill versions at $149/month; injectables for government programs at $245/month; Medicare $50 copay expected beginning in 2026). 2
- Pipeline momentum: Lilly said it will start Phase 3 for amylin‑pathway drug eloralintide in December 2025 after Phase 2 results matched high bar efficacy, reinforcing durability beyond GLP‑1s. 3
- Street reaction:BMO Capital lifted its LLY price target to $1,100 and reiterated Outperform, citing share gains and pipeline depth. 4
Eli Lilly stock today: quote & range
As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). 1
1) The White House’s obesity‑drug deal: lower prices, broader access
President Donald Trump announced deals with Eli Lilly and Novo Nordisk to reduce U.S. costs and expand coverage for in‑demand weight‑loss medicines. The plan includes Medicare coverage for obesity treatment, expected to carry $50 monthly copays for eligible beneficiaries, and a TrumpRx direct‑to‑consumer channel designed to bypass traditional middlemen. Reporting indicates starter doses of pill versions could be priced at $149/month, while injectables for Medicare/Medicaid would be $245/month; separate coverage notes the consumer‑facing TrumpRx price starting near $350/month, stepping down over time. The administration also pledged expedited FDA reviews for upcoming products. 2
Why this matters for LLY: Lower list prices can expand the addressable market and accelerate initiations, particularly among cost‑sensitive or needle‑averse patients—a cohort Lilly aims to reach with its oral GLP‑1, orforglipron, which is still on the 2025–2026 regulatory timeline. That volume opportunity can offset pricing pressure, especially given Lilly’s supply expansions. 5
2) New data: eloralintide delivers up to 20.1% weight loss; Phase 3 next month
Lilly reported Phase 2 data for eloralintide, a selective amylin receptor agonist dosed weekly. At 48 weeks, the highest dose achieved up to 20.1% average weight loss versus minimal change on placebo, with improvements in metabolic markers. Lilly said Phase 3 begins in December 2025. Coverage also notes tolerability consistent with gastrointestinal effects typical of incretin‑class therapies. 3
The company is presenting eloralintide content at ObesityWeek 2025, underscoring momentum in non‑GLP‑1 mechanisms that could complement tirzepatide (Zepbound) or expand options for patients who struggle with GLP‑1 side effects. 6
Investor read‑through: If Phase 3 confirms Phase 2 magnitude and durability, eloralintide would de‑risk Lilly’s multi‑mechanism obesity strategy (GLP‑1/GIP, amylin, and oral agents), easing reliance on any single product and potentially improving long‑term persistence. 3
3) Street reaction: BMO takes target to $1,100
Reflecting the policy and pipeline setup, BMO Capital raised its price target on LLY to $1,100 and reiterated Outperform, pointing to Lilly’s expanding lead in prescriptions and breadth of late‑stage assets. 4
Context that rounds out today’s move
- Supply build‑out: Earlier this week, Lilly unveiled a $3 billion plant in the Netherlands to scale oral medicine output (including obesity). Combined with prior U.S. investments, this should help address demand and support potential volume from today’s policy shift. 7
- Oral GLP‑1 timeline: Coverage today reiterates orforglipron is tracking toward FDA submission by late 2025 and a potential 2026 launch, positioning Lilly for broader penetration among patients who prefer pills over injections. 5
What to watch next
- Policy implementation: Rulemaking, timelines and eligibility details for Medicare coverage and TrumpRx rollout (pricing bands and copay mechanics)—these will drive adoption curves and net pricing. 2
- Eloralintide Phase 3 start (Dec 2025): Trial design, endpoints and duration will frame when investors can expect pivotal data and regulatory filing. 3
- Orforglipron milestones (late 2025–2026): Filing acceptance, label, and launch readiness (including manufacturing capacity). 5
- Q4/Q1 updates: Management’s commentary on supply, gross‑to‑net effects under the new pricing framework, and any color on payer contracting.
Bottom line
Today’s LLY strength is fundamentally about “more patients, sooner.” The White House agreement points to lower barriers to initiation and broader coverage, while eloralintide’s Phase 2 results and imminent Phase 3 start bolster Lilly’s vision of a multi‑mechanism, multi‑format obesity portfolio. Short‑term, investors will parse net price vs. volume; medium‑term, orforglipron and eloralintide could extend Lilly’s lead beyond injectable GLP‑1s. 2
Sources referenced today (Nov 6, 2025)
- Reuters stock page & news flow for live quote/range and deal coverage. 1
- Associated Press on policy specifics (coverage expansion, $50 copay). 2
- The Washington Post on pricing bands and expedited reviews. 8
- The Wall Street Journal and Financial Times on pricing details and market reaction. 9
- Reuters and Bloomberg on eloralintide efficacy and the Phase 3 start. 3
- BMO price‑target move via TheFly/TipRanks. 4
- Reuters on Dutch manufacturing expansion (context). 7
- Lilly Medical on ObesityWeek 2025 presentations (context). 6
This article is for information only and does not constitute investment advice. Investing involves risk, including possible loss of principal.
